What is the immediate management for a patient receiving intensive cytotoxic or cellular therapy (e.g., chimeric antigen receptor T‑cell therapy) who is at risk for tumor lysis syndrome, cytokine release syndrome, and neutropenic fever?

Immediate Management of TLS, CRS, and Neutropenic Fever in CAR T-Cell Therapy

For any patient with fever ≥38°C after intensive cytotoxic or CAR T-cell therapy, immediately obtain blood cultures and other infection workup, then start empiric broad-spectrum intravenous antibiotics along with symptomatic measures (antipyretics, fluids) before attempting to differentiate between neutropenic fever and cytokine release syndrome. 1

Initial Approach to Fever

The critical challenge is that fever in this population represents a diagnostic dilemma where neutropenic sepsis and CRS present identically, and both can coexist. 1, 2

Immediate Actions for Any Fever ≥38°C:

• Draw blood cultures, urine cultures, and perform chest imaging (X-ray or high-resolution CT when indicated) 1
• Initiate respiratory viral screening including COVID-19 and comprehensive viral panels 1
• Test for CMV and EBV by nucleic acid testing 1
• Consider lumbar puncture and brain MRI in selected cases with neurological symptoms 1
• Start empiric broad-spectrum IV antibiotics immediately based on institutional protocols, patient-specific risk factors (prior allo-HCT, previous infections, local resistance patterns), and duration of neutropenia 1
• Administer antipyretics and IV fluids for symptomatic management 1

Cytokine Release Syndrome Management Algorithm

Grade 1 CRS (Temperature ≥38°C, no hypotension, no hypoxia):

• Alert your local ICU for potential escalation 1
• Continue broad-spectrum antibiotics (already initiated per above) 1
• Consider preemptive tocilizumab 8 mg/kg IV (max 800 mg) if fever persists >24 hours, as this approach has been shown to prevent progression to severe CRS without increasing neurotoxicity or infection rates 3
• In children <30 kg, use tocilizumab 12 mg/kg 1

Grade 2 CRS (Temperature ≥38°C AND hypotension not requiring vasopressors OR hypoxia requiring low-flow oxygen ≤6 L/min):

• Administer tocilizumab 8 mg/kg IV (max 800 mg) in the hematology unit before ICU transfer 1
• Transfer to ICU (especially recommended in centers with limited CAR-T experience) 1
• If deterioration occurs, add dexamethasone 10 mg IV every 6 hours for 1-3 days 1
• May repeat tocilizumab (max 800 mg) if no improvement within 3 days and no alternative diagnosis 1
• Dexamethasone can be administered concurrently with the second tocilizumab dose if needed 1

Grade 3 CRS (Temperature ≥38°C AND hypotension requiring vasopressor OR hypoxia requiring high-flow oxygen >6 L/min or face mask):

• Give tocilizumab 8 mg/kg IV (max 800 mg) 1
• Transfer to ICU immediately 1
• Administer dexamethasone 10 mg IV every 6 hours for 1-3 days 1
• If deterioration continues, escalate to dexamethasone 20 mg IV every 6 hours for 3 days with progressive tapering over 3-7 days 1

Grade 4 CRS (Temperature ≥38°C OR hypotension requiring multiple vasopressors OR hypoxia requiring positive pressure ventilation):

• Administer tocilizumab 8 mg/kg IV (max 800 mg) 1
• Give dexamethasone 20 mg IV every 6 hours for 3 days 1
• If no improvement, switch to methylprednisolone 1000 mg/day IV for 3 days, then taper: 250 mg twice daily for 2 days, 125 mg twice daily for 2 days, 60 mg twice daily for 2 days 1
• Consider repeating tocilizumab (maximum 1 additional dose) in the absence of ICANS 1

Tumor Lysis Syndrome Prevention and Management

TLS should be prevented and managed using standard institutional protocols following lymphodepletion and CAR-T infusion. 1

Key TLS Prevention Strategies:

• Aggressive IV hydration to maintain high urine output 4
• Allopurinol or rasburicase for hyperuricemia control 4
• Close monitoring of electrolytes (potassium, phosphorus, calcium, uric acid) 4
• Monitor for metabolic disturbances: hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute renal failure 4

Neutropenic Fever Considerations

All patients will be neutropenic following lymphodepletion, making infection a universal concern. 1

Infection Risk Timeline:

• 0-30 days post-infusion: Bacterial infections predominate 5
• Beyond 30 days: Respiratory viral infections become more common 5
• Fungal and herpesvirus infections are less common but must be considered 5

Critical Pitfall:

Neutropenic fever is nearly universal after CAR-T therapy but is confounded by CRS, as both present with fever. 5 The key distinction is that CRS includes hypotension and/or hypoxia, but you must treat empirically for infection regardless because the differential diagnosis includes neutropenic sepsis. 1

ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) Monitoring

While managing the above complications, remain vigilant for neurological symptoms including tremor, confusion, agitation, seizures, dysphasia, hesitant speech, and deterioration in handwriting. 1

• Grade 1 ICANS: Supportive management only 1
• Grade 2 ICANS or higher: Corticosteroid therapy with rapid taper; consider ICU transfer 1
• Seizures: Treat with levetiracetam; status epilepticus requires benzodiazepines 1
• Tocilizumab has no clear role in ICANS and may contribute to its development 1

Key Clinical Pearls

• High fever (38.9°C) and hemodynamic instability within 36 hours of CAR-T infusion predicts severe ICANS with high sensitivity 1
• Steroids do not impact CAR-T efficacy for short courses, though prolonged courses may shorten progression-free survival 1
• Infections occur in 23-42% of CAR-T recipients, with risk factors including prior HCT, underlying malignancy, CRS severity, and neutropenia duration 5, 2
• Ideally hospitalize patients for 14 days post-infusion with 24/7 specialist availability 1